TEVA, US8816242098

Teva stock in focus after emrusolmin trial discontinuation

Published on 11/02/2026 at 15:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Teva stock faces a pipeline setback after an interim review found a low chance of meeting the study's main goal. No safety concerns were identified.

Teva halts mid-stage emrusolmin study

Teva will discontinue the Phase 2 TOPAS-MSA study after an interim review indicated a low probability of meeting its primary goal.
The review was predictive rather than a final efficacy analysis, and no safety concerns were identified.
The decision concerns the study and does not by itself establish the future of the wider emrusolmin program.

TEVA, US8816242098, Illustration mit AI erstellt.

Teva Pharmaceuticals said on Monday, November 2, 2026, that it will discontinue the Phase 2 TOPAS-MSA study of emrusolmin in adults with multiple system atrophy. The announcement was reported by Reuters.

An independent data monitoring committee recommended stopping the study after a planned interim analysis indicated a low probability that it would meet its main goal if continued. Teva said the assessment was predictive and was not the study's final efficacy analysis.

Pipeline setback without safety signal

Emrusolmin was being tested in patients with multiple system atrophy, a rare neurodegenerative disorder that can impair coordination and balance. The interim assessment identified no safety concerns, according to the report.

The decision removes the immediate Phase 2 development path for TOPAS-MSA, but the interim result does not settle the broader outlook for emrusolmin. The full interpretation depends on the completed analysis of the study.